PBMs, drugmakers face off over copay accumulators

PBMs, drugmakers face off over copay accumulators

As with most drug pricing battles, patients yet again are caught in the crossfire.

Survey: Half of women don't focus on their own health

Survey: Half of women don't focus on their own health

GCI Health, HealthyWomen, and Redbook magazine are using survey insights to inform the HealthiHer movement.

When TV doctors call you to make an appointment

When TV doctors call you to make an appointment

Actor Patrick Dempsey is helping patients get over the pressure of scheduling an appointment

Pro ad report 2017: Ad revenue plunged for print-first publishers

Pro ad report 2017: Ad revenue plunged for print-first publishers

The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.

AbbVie veteran Mark Stenhouse joins Cologuard as president

AbbVie veteran Mark Stenhouse joins Cologuard as president

He spent more than 30 years at the pharmaceutical company.

ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?

ePharma: Novo Nordisk's lessons from a diabetes education campaign

ePharma: Novo Nordisk's lessons from a diabetes education campaign

Why the drugmaker's partnership with a YouTube star is still getting hits.

Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?

Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?

As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.

DTC pharma ad spending slipped 4.6% in 2017: Kantar

DTC pharma ad spending slipped 4.6% in 2017: Kantar

Direct-to-consumer drug marketing spend dropped most heavily in the magazine and digital categories.